SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Plain-language summary
This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
SHR2554; Chidamide analog tablets (DRUG): SHR2554 + Chidamide analog tablets | SHR2554 analog tablets; Chidamide (DRUG): SHR2554 analog tablets + Chidamide
SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details